Pronota presents foun­da­tion of Next Generation Sequencing appli­ca­tion to iden­ti­fy and quan­ti­fy pro­teins.

Ghent, Belgium, 19th May 2010 – Pronota, the Belgian devel­op­er of pro­tein bio­mark­er diag­nos­tics, announced today its suc­cess­ful proof of con­cept of a nov­el, diag­nos­tic plat­form. The com­pa­ny reports the first Next Generation Sequencing (NGS) appli­ca­tion to iden­ti­fy and quan­ti­fy pro­teins.

The advent of Next Generation Sequencing tech­nol­o­gy estab­lished a nov­el ref­er­ence in nucleotide sequenc­ing. Processing hun­dreds of thou­sands to mil­lions of DNA mol­e­cules in par­al­lel enabled a broad range of bio­log­i­cal appli­ca­tions, from whole genome sequenc­ing to tran­script pro­fil­ing.

Attracted by the unique ana­lyt­i­cal capa­bil­i­ties of NGS we have proven it could also be applied beyond the sequenc­ing of DNA and RNA. Together with aca­d­e­m­ic researchers from the UK and Belgium, Pronota com­bined NGS with aptamer1 tech­nol­o­gy. This nov­el con­cept relies on the under­stand­ing that aptamers can both cap­ture the iden­ti­ty as well as quan­ti­ta­tive infor­ma­tion of an ana­lyte (pro­teins, small mol­e­cules, cells…). This infor­ma­tion can then eas­i­ly be decod­ed by quan­ti­ta­tive sequenc­ing of the ana­lyte-bound aptamers. Using this approach, Pronota was able to trans­late serum Immunoglobulin E lev­els into aptamer counts, demon­strat­ing the poten­tial of this method as a nucleotide sequenc­ing-based pro­tein bio­mark­er dis­cov­ery and diag­nos­tics plat­form.

Commenting on the devel­op­ment, the sub­ject of filed patent appli­ca­tions, Dr Koen Kas, founder and CSO of Pronota said: “This is a trans­for­ma­tion­al mile­stone in the merg­ing of genomics and pro­teomics. With this explorato­ry research we believe we have estab­lished some of the cor­ner stones of a nov­el par­a­digm, which will allow us and oth­ers to build on this idea. The intrin­sic abil­i­ty of aptamer sequenc­ing to detect and quan­ti­fy pro­teins in a high­ly mul­ti­plexed fash­ion, togeth­er with the prospect of DNA sequenc­ing fur­ther evolv­ing into a com­mod­i­ty tech­nol­o­gy, could result in the most ver­sa­tile diag­nos­tics plat­form known”.

The nov­el con­cept will be pre­sent­ed dur­ing a talk at Knowledge for Growth, the annu­al life sci­ences con­ven­tion in Ghent, Belgium, tak­ing place on May 20, 2010.

Leave a Reply

Your email address will not be published. Required fields are marked *